JP6392752B2 - （１ｅ，６ｅ）−１，７−ビス−（３，４−ジメトキシフェニル）−４，４−ジ置換−ヘプタ−１，６−ジエン−３，５−ジオン構造足場を伴う化合物、その生物活性、およびその使用 - Google Patents

（１ｅ，６ｅ）−１，７−ビス−（３，４−ジメトキシフェニル）−４，４−ジ置換−ヘプタ−１，６−ジエン−３，５−ジオン構造足場を伴う化合物、その生物活性、およびその使用 Download PDF

Info

Publication number
JP6392752B2
JP6392752B2 JP2015518483A JP2015518483A JP6392752B2 JP 6392752 B2 JP6392752 B2 JP 6392752B2 JP 2015518483 A JP2015518483 A JP 2015518483A JP 2015518483 A JP2015518483 A JP 2015518483A JP 6392752 B2 JP6392752 B2 JP 6392752B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
androgen receptor
aromatic
related medical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015518483A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015520233A5 (https=
JP2015520233A (ja
Inventor
シー，チャールズ
シャイ，チアン
ワン，ホイ−カン
スー，チン−ユアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allianz Pharmascience Ltd
Original Assignee
Allianz Pharmascience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/525,941 external-priority patent/US8710272B2/en
Application filed by Allianz Pharmascience Ltd filed Critical Allianz Pharmascience Ltd
Publication of JP2015520233A publication Critical patent/JP2015520233A/ja
Publication of JP2015520233A5 publication Critical patent/JP2015520233A5/ja
Application granted granted Critical
Publication of JP6392752B2 publication Critical patent/JP6392752B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015518483A 2012-06-18 2013-06-17 （１ｅ，６ｅ）−１，７−ビス−（３，４−ジメトキシフェニル）−４，４−ジ置換−ヘプタ−１，６−ジエン−３，５−ジオン構造足場を伴う化合物、その生物活性、およびその使用 Active JP6392752B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/525,941 2012-06-18
US13/525,941 US8710272B2 (en) 2007-01-08 2012-06-18 Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
PCT/US2013/046138 WO2013192091A1 (en) 2012-06-18 2013-06-17 Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018090272A Division JP2018135386A (ja) 2012-06-18 2018-05-09 （１ｅ，６ｅ）−１，７−ビス−（３，４−ジメトキシフェニル）−４，４−ジ置換−ヘプタ−１，６−ジエン−３，５−ジオン構造足場を伴う化合物、その生物活性、およびその使用 関連出願の相互参照

Publications (3)

Publication Number Publication Date
JP2015520233A JP2015520233A (ja) 2015-07-16
JP2015520233A5 JP2015520233A5 (https=) 2016-09-15
JP6392752B2 true JP6392752B2 (ja) 2018-09-19

Family

ID=49769258

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015518483A Active JP6392752B2 (ja) 2012-06-18 2013-06-17 （１ｅ，６ｅ）−１，７−ビス−（３，４−ジメトキシフェニル）−４，４−ジ置換−ヘプタ−１，６−ジエン−３，５−ジオン構造足場を伴う化合物、その生物活性、およびその使用
JP2018090272A Abandoned JP2018135386A (ja) 2012-06-18 2018-05-09 （１ｅ，６ｅ）−１，７−ビス−（３，４−ジメトキシフェニル）−４，４−ジ置換−ヘプタ−１，６−ジエン−３，５−ジオン構造足場を伴う化合物、その生物活性、およびその使用 関連出願の相互参照

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018090272A Abandoned JP2018135386A (ja) 2012-06-18 2018-05-09 （１ｅ，６ｅ）−１，７−ビス−（３，４−ジメトキシフェニル）−４，４−ジ置換−ヘプタ−１，６−ジエン−３，５−ジオン構造足場を伴う化合物、その生物活性、およびその使用 関連出願の相互参照

Country Status (14)

Country Link
EP (3) EP3150203B1 (https=)
JP (2) JP6392752B2 (https=)
KR (1) KR102171469B1 (https=)
CN (3) CN104755076A (https=)
AU (1) AU2013277423B2 (https=)
CA (1) CA2876957C (https=)
DK (1) DK3150203T3 (https=)
ES (1) ES2775173T3 (https=)
HK (1) HK1211211A1 (https=)
IN (1) IN2015MN00131A (https=)
MX (1) MX2014015936A (https=)
NZ (1) NZ703167A (https=)
SG (1) SG11201408387YA (https=)
WO (1) WO2013192091A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019138742A (ru) 2017-05-26 2021-06-28 Бруин Байосаенсис, Инк. Средства для химиоэмболизации
CN107226783B (zh) * 2017-06-20 2019-07-23 武汉工程大学 一种溶酶体靶向荧光探针及其制备方法
EP3508855A1 (en) * 2018-01-05 2019-07-10 Allianz Pharmascience Ltd Method for the selection of patients and kit
US11135185B2 (en) 2018-03-23 2021-10-05 Merry Life Biomedical Company, Ltd. Uses of curcumin derivative
JP2020117489A (ja) * 2019-01-04 2020-08-06 アリアンツ ファーマサイエンス リミテッド 脳癌の治療方法
JP2020125285A (ja) * 2019-01-04 2020-08-20 アリアンツ ファーマサイエンス リミテッド 神経変性性障害の治療方法
CN110183320B (zh) * 2019-04-15 2021-06-11 四川大学 一类多烯二酮类抗肿瘤化合物
CN116969828A (zh) * 2022-04-29 2023-10-31 南京迈诺威医药科技有限公司 一种具备抗雄激素受体活性的化合物及其用途
CN116120182A (zh) * 2023-02-16 2023-05-16 常州大学 姜黄素衍生物及其合成方法和在抗雄激素受体中的应用
CN116283676B (zh) * 2023-03-24 2025-03-28 常州大学 一种姜黄素衍生物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US812408A (en) 1905-08-19 1906-02-13 Roy Ernest Dickerson Educational device for teaching spherics.
US7355081B2 (en) * 2002-04-17 2008-04-08 The University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
US6790979B2 (en) * 2002-04-17 2004-09-14 University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
JP2010515685A (ja) * 2007-01-08 2010-05-13 アンドロサイエンス コーポレーション （置換フェニル）−プロペナール部分を伴う化合物、その誘導体、生物学的活性およびその使用
CN101820765A (zh) * 2007-07-31 2010-09-01 安德鲁科技有限公司 包含雄激素受体降解(ard)增强剂的组合物和预防性或治疗性治疗皮肤病与脱发的方法
US20090282496A1 (en) * 2008-04-04 2009-11-12 University Of Rochester Medical Center Androgen Receptor Related Methods for Treating Bladder Cancer

Also Published As

Publication number Publication date
KR20150023012A (ko) 2015-03-04
CN110279680A (zh) 2019-09-27
HK1211211A1 (en) 2016-05-20
EP3549581A3 (en) 2020-02-19
CA2876957C (en) 2021-02-16
WO2013192091A1 (en) 2013-12-27
ES2775173T3 (es) 2020-07-24
DK3150203T3 (da) 2020-04-14
EP3150203A1 (en) 2017-04-05
EP3549581A2 (en) 2019-10-09
CA2876957A1 (en) 2013-12-27
AU2013277423B2 (en) 2018-08-09
SG11201408387YA (en) 2015-01-29
MX2014015936A (es) 2016-06-24
AU2013277423A1 (en) 2015-01-22
JP2015520233A (ja) 2015-07-16
EP2861222A1 (en) 2015-04-22
JP2018135386A (ja) 2018-08-30
CN106220507A (zh) 2016-12-14
KR102171469B1 (ko) 2020-10-30
NZ703167A (en) 2016-09-30
EP2861222A4 (en) 2015-08-05
EP3150203B1 (en) 2020-02-19
IN2015MN00131A (https=) 2015-10-16
CN104755076A (zh) 2015-07-01

Similar Documents

Publication Publication Date Title
JP5998117B2 (ja) （置換フェニル）−プロペナール部分を伴う化合物、その誘導体、生物学的活性およびその使用
JP6392752B2 (ja) （１ｅ，６ｅ）−１，７−ビス−（３，４−ジメトキシフェニル）−４，４−ジ置換−ヘプタ−１，６−ジエン−３，５−ジオン構造足場を伴う化合物、その生物活性、およびその使用
US9562025B2 (en) Compounds with (1E, 6E)-1,7-Bis-(3,4-dimethoxyphenyl)-4-4-distributed-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
US8710272B2 (en) Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
HK1227380A1 (en) Compounds with (1e, 6e)-1, 7-bis-(3, 4-dimethoxyphenyl)-4, 4-disubstituted-hepta-1, 6-diene-3, 5-dione structural scaffold, and uses thereof
HK1222168B (en) Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof
HK1143802B (en) Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and uses thereof

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160607

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170721

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171017

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180509

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180709

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180724

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180823

R150 Certificate of patent or registration of utility model

Ref document number: 6392752

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250